SIGLEC7

Across TCGA pan-cancer cohorts, SIGLEC7 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated SIGLEC7 data layer compared with 22 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher SIGLEC7 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated SIGLEC7 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, HNSC, and GBM are the cancer types where SIGLEC7 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	III,IV	0.567	0.214	.033	5	view →
HNSC	DFS	Median	II,III,IV	0.866	1.000	.020	5	view →
GBM	OS	Quartile	All	0.398	0.713	.009	4	view →
LSCC	OS	Quartile	III,IV	0.970	0.570	.042	2	view →
LUAD	DFS	Median	All	0.705	0.486	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

SIGLEC7–PDAC (DFS)

Open the PDAC breakdown →